IRIS
PLAZ TORRES, MARIA CORINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 773
Totale 773
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 773
Totale 773
Salva come PNG Salva come JPEG
Città #
Genova 385
Genoa 230
Rapallo 150
Bordighera 8
Totale 773
Salva come PNG Salva come JPEG
Nome #
Low Fibrinogen Levels Are Associated with Bleeding After Varices Ligation in Thrombocytopenic Cirrhotic Patients 92
Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered 75
Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis 72
Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation 63
Risk factors for bleeding following oesophageal band ligation: Providing further evidence to ameliorate clinical practice 52
Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? 50
Liver Resection for Patients with Intermediate Stage Hepatocellular Carcinoma: Beyond Rigid Staging Systems Towards a More Personalized Therapeutic Approach 45
Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma 43
Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease? 40
Is there an "ideal" diet for patients with NAFLD? 39
Diabetes Medications and Risk of Hepatocellular Carcinoma 37
Global multi-stakeholder endorsement of the MAFLD definition 35
Use of non-invasive scores for the estimation of mortality risk in patients with Non-Alcoholic Fatty Liver Disease 32
Obeticholic Acid Improves Aminotransferases Early during Treatment in Patients with Primary Biliary Cholangitis Not Responding to Ursodeoxycholic Acid: A Study in Clinical Practice 31
Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting 26
Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma 22
Immune checkpoint inhibitors in malignancies after liver transplantation: a systematic review and pooled analysis 16
Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma 11
Safety and efficacy of venous thromboembolism prophylaxis in patients with cirrhosis: A systematic review and meta-analysis 10
Reply: novel antidiabetic drugs and the risk for hepatocellular carcinoma. What else to expect from these "wonderful" drug classes? 9
Food Intolerances, Food Allergies and IBS: Lights and Shadows 9
Albumin-bilirubin score in non-malignant liver diseases should be properly validated 9
Letter to the Editor: Is CAD-LT score as a predictor of coronary artery disease following liver transplantation? 8
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept 7
SAFETY AND EFFICACY OF ATEZOLIZUMAB/ BEVACIZUMAB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AND IMPAIRED LIVER FUNCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS 6
Liver Resection vs Nonsurgical Treatments for Patients With Early Multinodular Hepatocellular Carcinoma 5
Characteristics and outcome of anti‐hepatitis D virus positive patients with hepatocellular carcinoma 4
Hepatocellular carcinoma in patients with Autoimmune Hepatitis 3
Towards an integrated management model for hepatocellular carcinoma 2
Totale 853
Salva come PNG Salva come JPEG
Categoria #
all - tutte 5.865
article - articoli 5.709
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.574
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020125 1 0 0 6 5 18 23 14 14 19 13 12
2020/2021122 6 9 2 11 7 0 5 30 11 19 2 20
2021/2022172 15 6 1 6 8 8 7 32 29 27 9 24
2022/2023203 19 21 9 2 17 18 14 13 32 12 45 1
2023/2024205 12 20 4 35 22 13 12 14 9 11 20 33
2024/202523 23 0 0 0 0 0 0 0 0 0 0 0
Totale 853